coronavirus vaccine

November 16, 2020 | Brendan Hartlove

Novavax Releases $1.6 Billion Government Contract for COVID-19 Vaccine

Novavax, a vaccine development company in Gaithersburg, Md., released details for a $1.6 billion government contract for a COVID-19 vaccine on Nov. 11, according to NPR. The contract is part of the Trump Administration’s “Operation Warp Speed,” a program to make a vaccine available to the public in record time. Over the past several months, […]

Read more

August 12, 2020 | Isabel Cleary

Gaithersburg-Based Novavax Included in New York Times’ Coronavirus Vaccine Tracker

The New York Times has published a coronavirus vaccine tracker that shows the progress of the more than 165 vaccines in development, and the 30 that are in human trials. The coronavirus pandemic has forced researchers to condense years of research and testing into a shorter time frame, with the goal to produce a safe […]

Read more

August 5, 2020 | Shauneen Miranda

Novavax’s COVID-19 Vaccine Generates Positive Results in Phase 1 Trial

The Gaithersburg-based biotechnology company Novavax reported positive results Tuesday in phase 1 of its clinical trial for a potential COVID-19 vaccine. Promising news #MadeInMontgomery. — Montgomery Council (@MoCoCouncilMD) August 4, 2020 In early July, Novavax received $1.6 billion in funding as part of the federal government’s Operation Warp Speed, an initiative aiming to accelerate […]

Read more

July 29, 2020 | Shauneen Miranda

Fujifilm Joins Novavax’s Production List for COVID-19 Vaccine

The Tokyo-based Fujifilm Diosynth Biotechnologies joined other companies Monday in helping Gaithersburg’s Novavax produce and distribute the first batch of a potential COVID-19 vaccine to be used in clinical trials.  Novavax will be making its Covid-19 vaccine candidate with help Fujifilm Diosynth Biotechnologies, part of the $1.6 billion the Gaithersburg biotech secured from the federal […]

Read more

July 10, 2020 | Michelle Queen

Novavax in Gaithersburg Awarded 1.6 Billion Grant for COVID-19 Vaccine Development

The Federal government recently awarded Gaithersburg-based biotech company Novavax 1.6 billion in funding to develop and distribute 100 million COVID-19 vaccines as early as the end of this year. County Cable Montgomery’s Susan Kenedy spoke with Jim Young, the Novavax Chairman of the Board, about the work being done at Novavax. He explained why the […]

Read more

May 26, 2020 | Maryam Shahzad

Gaithersburg Vaccine Development Company Testing Candidate for COVID-19

A vaccine development company headquartered in Gaithersburg is starting clinical trials for a potential COVID-19 vaccine.  Novavax will administer the trials for vaccine candidate NVX‑CoV2373 in two phases, a statement from the company says. Phase 1 will test 131 people in Australia for immune response and safety. Results are expected in July. “Administering our vaccine […]

Read more

May 11, 2020 | Deirdre Byrne

Metro Operations May Not be Back to Normal Until Spring 2021

Washington Metropolitan Area Transit Authority released its multi-phased COVID-19 recovery plan Monday, indicating it may not return to its normal operations until Spring 2021. On Saturday, Paul Wiedefeld, general manager and CEO of WMATA, penned an op-ed in the Washington Post, saying, “Until a vaccine is available, our customer experience can’t be what it was […]

Read more

April 22, 2020 | Jordan Lindsay

Gaithersburg Lab One Step Closer to Potential COVID-19 Vaccine

A local bio-technology company has found a coronavirus vaccine candidate, and the first in-human trial is expected to begin in May. Novavax, which is located in Gaithersburg, develops next-generation vaccines for serious infectious diseases. Officials say they will be using NVX-CoV2373, which is described as a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. “Our scientists […]

Read more

Engage us on Facebook

Follow us on Twitter